Pegvisomant: Difference between revisions
No edit summary |
|||
Line 1: | Line 1: | ||
{{ | {{SI}} | ||
{{Editor Help}} | |||
'''Pegvisomant''' is a [[growth hormone]] receptor [[antagonist]] commonly used in the treatment of [[acromegaly]]. | '''Pegvisomant''' is a [[growth hormone]] receptor [[antagonist]] commonly used in the treatment of [[acromegaly]]. | ||
{{Pituitary and hypothalamic hormones and analogues}} | {{Pituitary and hypothalamic hormones and analogues}} | ||
[[Category:Endocrinology]] | |||
{{SIB}} | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} |
Revision as of 19:14, 19 December 2011
WikiDoc Resources for Pegvisomant |
Articles |
---|
Most recent articles on Pegvisomant Most cited articles on Pegvisomant |
Media |
Powerpoint slides on Pegvisomant |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Pegvisomant at Clinical Trials.gov Clinical Trials on Pegvisomant at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Pegvisomant
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Pegvisomant Discussion groups on Pegvisomant Patient Handouts on Pegvisomant Directions to Hospitals Treating Pegvisomant Risk calculators and risk factors for Pegvisomant
|
Healthcare Provider Resources |
Causes & Risk Factors for Pegvisomant |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Pegvisomant is a growth hormone receptor antagonist commonly used in the treatment of acromegaly.
Template:Pituitary and hypothalamic hormones and analogues Template:SIB